Literature DB >> 16430712

Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management.

Filomena Cetani1, Elena Pardi, Elena Ambrogini, Monica Lemmi, Simona Borsari, Luisella Cianferotti, Edda Vignali, Paolo Viacava, Piero Berti, Stefano Mariotti, Aldo Pinchera, Claudio Marcocci.   

Abstract

OBJECTIVE: Familial isolated primary hyperparathyroidism (FIPH) can result from either incomplete expression of a syndromic form of familial primary hyperparathyroidism [multiple endocrine neoplasia type 1 (MEN 1), hyperparathyroidism-jaw tumour syndrome (HPT-JT) or familial hypocalciuric hypercalcaemia (FHH)] or still unrecognized causes. Design Genetic analyses of MEN1, HRPT2 and CASR genes in FIHP. PATIENTS: Seven well-characterized Italian kindreds with FIHP, with negative clinical features for MEN 1, HPT-JT and FHH. The mean age (+/- SD) at diagnosis was 45 +/- 17 years (range 18-70 years) in the probands and 42 +/- 18 years (range 15-69 years) in the other affected subjects. MEASUREMENTS: Direct sequencing of germline DNA of the MEN1, HRPT2 and CASR genes from probands. The region of interest was amplified in some family members.
RESULTS: Germline MEN1 mutations were detected in three kindreds. Multiglandular involvement was found in all but one affected subject belonging to the three kindreds with MEN1 mutations. In these patients persistence/relapse of the disease was observed unless an extensive parathyroidectomy (excision of 3(1)/(2) glands) had been performed, with the exception of one patient, who is currently normocalcaemic 168 months after excision of two glands. No mutations of MEN1, HRPT2 and CASR genes were identified in the remaining four families.
CONCLUSIONS: MEN1 genotyping appears worthwhile in FIHP families, as the finding of mutation(s) may predict multiglandular involvement and therefore have practical surgical implications, and prompt further investigation in the family, with the possibility of identifying new cases and beginning a programme of periodic surveillance for emergence of tumours in all carriers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430712     DOI: 10.1111/j.1365-2265.2006.02438.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

Review 2.  Genetic basis of familial isolated hyperparathyroidism: a case series and a narrative review of the literature.

Authors:  Nikolaos Pontikides; Spyridon Karras; Athina Kaprara; Panagiotis Anagnostis; Gesthimani Mintziori; Dimitrios G Goulis; Eleni Memi; Gerasimos Krassas
Journal:  J Bone Miner Metab       Date:  2014-01-19       Impact factor: 2.626

3.  New Concepts About Familial Isolated Hyperparathyroidism.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2019-03-08       Impact factor: 5.958

Review 4.  Genetics of Hyperparathyroidism, Including Parathyroid Cancer.

Authors:  William F Simonds
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-23       Impact factor: 4.741

Review 5.  Clinical and molecular genetics of parathyroid neoplasms.

Authors:  John M Sharretts; William F Simonds
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 6.  Parathyroid carcinoma.

Authors:  B Givi; J P Shah
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-05-26       Impact factor: 4.126

Review 7.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

8.  Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age?

Authors:  Anita Skandarajah; Anne Barlier; Nathalie Morlet-Barlat; Frederic Sebag; Alain Enjalbert; Bernard Conte-Devolx; Jean-François Henry
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

9.  Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.

Authors:  O Vierimaa; A Villablanca; A Alimov; M Georgitsi; A Raitila; P Vahteristo; C Larsson; A Ruokonen; E Eloranta; T M L Ebeling; J Ignatius; L A Aaltonen; J Leisti; P I Salmela
Journal:  J Endocrinol Invest       Date:  2009-03-26       Impact factor: 4.256

10.  Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure.

Authors:  Mustapha El Lakis; Pavel Nockel; Bin Guan; Sunita Agarwal; James Welch; William F Simonds; Stephen Marx; Yulong Li; Naris Nilubol; Dhaval Patel; Lily Yang; Roxanne Merkel; Electron Kebebew
Journal:  Surgery       Date:  2017-11-03       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.